Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL577885 | 0.78 | — | — | |
| SCHEMBL290242 | 0.77 | HDAC6 (0.36) | — | |
| SCHEMBL15225423 | 0.75 | CA1 (0.33) | — | |
| SCHEMBL15672939 | 0.73 | LPL (0.36) | — | |
| SCHEMBL2354652 | 0.72 | — | — | |
| SCHEMBL15225080 | 0.72 | DAO (0.37) | DAO | |
| SCHEMBL486247 | 0.71 | SMN1; SMN2 (0.30) | — | |
| SCHEMBL18209350 | 0.70 | — | — | |
| SCHEMBL17802975 | 0.70 | — | — | |
| SCHEMBL14782594 | 0.69 | HCAR2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136598-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-01 | — | — | US | disclosed |
| US-12172997-B2 | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-24 | — | — | US | disclosed |
| US-20230151006-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| US-11618750-B2 | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-04 | — | — | US | disclosed |
| EP-3983075-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-04-20 | — | — | EP | disclosed |
| US-20210017168-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-21 | — | — | US | disclosed |
| WO-2020249792-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
| EP-3720852-A1 | FLUOROPHENYL SUBSTITUTED MUSCARINIC RECEPTOR LIGANDS WITH SELECTIVITY FOR M3 OVER M2 | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-10-14 | — | — | EP | disclosed |
| US-20200308168-A1 | FLUOROPHENYL SUBSTITUTED MUSCARINIC RECEPTOR LIGANDS WITH SELECTIVITY FOR M3 OVER M2 | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-10-01 | — | — | US | disclosed |
| US-10439141-B2 | P-type semiconducting polymers and related methods | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-10-08 | — | — | US | disclosed |
| US-20130190293-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-07-25 | — | — | US | disclosed |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2013085957-A1 | SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-06-13 | — | — | WO | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| WO-2012154261-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012112963-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012112966-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012112962-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| WO-2011103430-A1 | PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190293-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR4, HTR3B, HTR2C | DAO 206/4885 |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | DAO 432/4885 |
| US-12172997-B2 | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN3A | DAO 1041/4885 |
| US-20230151006-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR | GRIN2B, GRIN2A, GRIN3A | DAO 848/4885 |
| US-20130190294-A1 | COMPOUNDS AND METHODS FOR TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | DAO 212/4885 |
| US-20250136598-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3A | DAO 1041/4885 |
| US-20200308168-A1 | FLUOROPHENYL SUBSTITUTED MUSCARINIC RECEPTOR LIGANDS WITH SELECTIVITY FOR M3 OVER M2 | CHRM2, CHRM3, CHRM5 | DAO 785/4885 |
| US-11618750-B2 | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN3A | DAO 1041/4885 |
| US-20210017168-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3A | DAO 1041/4885 |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | DAO 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.